PUBLIC COMPANY
save$KLRAKailera Therapeutics, Inc.
$KLRA13.70+5.63%Waltham, MA, USupdated 10d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
Where Kailera Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaMetabolic 24Oncology 1
News
- The 6 biggest crossover rounds in biopharma historyA strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to Sofinnova Investments’ Jim Healy.biospace · 1mo ago
- Hengrui has become the go-to source of China biopharma innovation. What’s its secret?Amid the Chinese biotech licensing boom, Hengrui Pharmaceuticals stands out from the crowd. The Jiangsu-based biopharma landed one of the largest licensing deals ever by a Chinese company courtesy…fiercebiotech · 1mo ago
- Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechJennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…biospace · 3mo ago
- Biotech startup funding gap widens despite rebound in VC investmentThough funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.biopharma_dive · 4mo ago
- At BIO, tension over China biotech deal regulation loomsBiotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.biopharma_dive · 4mo ago
- Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billionThe wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.biopharma_dive · 6mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that